We are live on ! Find out more
SCLN

Sciclone Pharmaceuticals Inc
SCLN

Delisted

SCLN was delisted on the 13th of October, 2017.

134 hedge funds and large institutions have $860M invested in Sciclone Pharmaceuticals Inc in 2015 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 49 increasing their positions, 56 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

22,000% more call options, than puts

Call options by funds: $221K | Put options by funds: $1K

124% more capital invested

Capital invested by funds: $383M → $860M (+$477M)

8% less funds holding

Funds holding: 146134 (-12)

13% less repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 56

44% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 27

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
134
Holders Change
-12
Holders Change %
-8.22%
% of All Funds
3.74%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
15
Increased
49
Reduced
56
Closed
27
Calls
$221K
Puts
$1K
Net Calls
+$220K
Net Calls Change
-$295K
Name Holding Trade Value Shares
Change
Change in
Stake
ACM
1
Americafirst Capital Management
California
$607M -$220K -25,650 -23%
Franklin Resources
2
Franklin Resources
California
$30.9M +$1.53M +178,900 +4%
Dimensional Fund Advisors
3
Dimensional Fund Advisors
Texas
$17.4M +$433K +50,589 +2%
BIT
4
BlackRock Institutional Trust
California
$14.9M -$941K -109,851 -5%
BFA
5
BlackRock Fund Advisors
California
$14.2M +$494K +57,670 +3%
State Street
6
State Street
Massachusetts
$13.9M +$1.36M +158,832 +9%
Acadian Asset Management
7
Acadian Asset Management
Massachusetts
$12.8M -$812K -94,800 -5%
Vanguard Group
8
Vanguard Group
Pennsylvania
$11.8M -$2.5M -292,410 -15%
LSV Asset Management
9
LSV Asset Management
Illinois
$11.3M -$25.6K -2,985 -0.2%
SI
10
Sensato Investors
California
$10.9M -$1.76M -205,100 -12%
Morgan Stanley
11
Morgan Stanley
New York
$6.33M +$2.22M +259,588 +40%
AQR Capital Management
12
AQR Capital Management
Connecticut
$5.35M +$1.82M +212,235 +38%
BA
13
BlackRock Advisors
Delaware
$5.25M -$67.7K -7,905 -1%
Northern Trust
14
Northern Trust
Illinois
$5.03M +$581K +67,880 +10%
NI
15
Numeric Investors
Massachusetts
$4.94M -$4.06M -473,534 -40%
QI
16
QS Investors
New York
$4.62M -$1.38M -160,792 -19%
Charles Schwab
17
Charles Schwab
California
$3.71M +$349K +40,791 +8%
Renaissance Technologies
18
Renaissance Technologies
New York
$3.08M -$2.13M -248,160 -36%
GT
19
Glenmede Trust
Pennsylvania
$2.86M +$453K +52,926 +15%
RFC
20
Russell Frank Company
Washington
$2.81M +$2M +233,663 +136%
D.E. Shaw & Co
21
D.E. Shaw & Co
New York
$2.8M +$1.45M +168,886 +72%
Fisher Asset Management
22
Fisher Asset Management
Washington
$2.77M +$3.41M +398,426 New
SAMC
23
Shinko Asset Management Company
Japan
$2.77M +$3.41M +398,426 New
Wellington Management Group
24
Wellington Management Group
Massachusetts
$2.52M +$396K +46,201 +15%
Geode Capital Management
25
Geode Capital Management
Massachusetts
$2.27M -$270K -31,472 -9%

SCLN Hedge Fund Activity: Q3 2015 in Review

134 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q3 2015, worth a combined $860M — up 124% from $383M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of SCLN and 15 opened new positions — a net loss of 12 holders — while 56 trimmed existing stakes and 49 added.

The largest buyer was Fisher Asset Management, opening a new position worth an estimated $3.41M. The largest seller was Nantahala Capital Management, cutting an estimated $7.65M.

  • 134 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q3 2015, down from 146 in Q2 2015.
  • Funds reported $860M of Sciclone Pharmaceuticals Inc stock for Q3 2015, up 124% quarter-over-quarter.
  • 15 funds opened new Sciclone Pharmaceuticals Inc positions in Q3 2015 and 27 closed out, a net change of -12 holders.
  • The largest Sciclone Pharmaceuticals Inc buyer in Q3 2015 was Fisher Asset Management, an estimated $3.41M added.
  • The largest Sciclone Pharmaceuticals Inc seller in Q3 2015 was Nantahala Capital Management, an estimated $7.65M sold.

Based on aggregated 13F filings for Q3 2015.